Yong (Ben) Ben, M.D., MBA, has over 20 years of medical experience in academia and pharmaceutical & biotech companies, including clinical practice, drug discovery and development in oncology. He joined BeiGene in February 2019 as Chief Medical Officer, Immuno-Oncology. Prior to joining BeiGene, Dr. Ben served as Chief Medical Officer at San Diego-based biotech company BioAtla and concurrently as co-founder, Chief Medical Officer & President at Himalaya Therapeutics focusing on oncology drug development of BioAtla’s pipeline in China. Previously, he was global clinical leader of immuno-oncology clinical development at AstraZeneca, leading the approval of durvalumab in urothelial cancer. Dr. Ben’s career highlights also include his work on the approval of ixazomib in multiple myeloma at Millennium Pharmaceuticals and the approval of axitinib in renal cancer at Pfizer.

Throughout his career, Dr. Ben has led wide-spectrum clinical development efforts from Phase I to Phase 3 trials from strategy planning, and study execution, to BLA/NDA submissions. He started his career as a surgical oncologist at Peking Union Medical College Hospital and completed a postdoctoral fellowship at California Pacific Medical Center. Dr. Ben received his medical degree from Norman Bethune College of Medicine and his MBA from the University of California, San Diego.